Nanospectra
Houston, US · 2 known investors
Find your way into Nanospectra
Nanospectra Biosciences is a medical device company developing nanoparticle-based thermal ablation therapy that uses light-activated nanoshells to destroy solid tumors, such as prostate cancer, while sparing healthy tissue. Its technology targets clinical applications in tumor ablation, tissue treatment, and drug delivery.
Founders & leadership
JW
Jennifer WestFounder
PP
Patrick PaceExecutive
DJ
David JordenExecutive
GG
Glenn GoodrichExecutive
Board
BN
Bradley NybergBoard director
DB
David BristolBoard director
BS
Blair ShamelBoard director
Investors · 2
Also in the syndicate · 1
Sirtex Medicallead
Reported raises · per SEC filings
Form D private placements$18.5M disclosed across 5 rounds · 2014–2023
▶$6.1MraisedMar 2023 · 51 investors · Other Health CareRule 506(b)
▶$6.1MraisedMar 2023 · 51 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Blair ShamelDirector
- Kevin P. SmithDirector
- Patrick PaceDirector
- Bradley NybergDirector
- David JordenExecutive Officer, Director
- Glenn GoodrichExecutive Officer
- Offering amount
- $10.1M
- Amount sold
- $6.1M
- First sale
- Feb 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$8.6MraisedAug 2021 · 41 investors · Other Health CareRule 506(b)
▶$8.6MraisedAug 2021 · 41 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Blair ShamelDirector
- Glenn GoodrichExecutive Officer
- Patrick PaceExecutive Officer, Director
- Kevin P. SmithDirector
- Bradley NybergDirector
- David JordenExecutive Officer, Director
- Offering amount
- $11.3M
- Amount sold
- $8.6M
- First sale
- Sep 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2MraisedFeb 2017 · 19 investors · Other Health CareRule 506(b)
▶$2MraisedFeb 2017 · 19 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Brian PryorDirector
- Blair ShamelDirector
- Glenn GoodrichExecutive Officer
- David JordenExecutive Officer, Director
- Bradley NybergDirector
- Patrick PaceExecutive Officer, Director
- Offering amount
- $4.2M
- Amount sold
- $2M
- First sale
- Jan 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$946KraisedDec 2015 · 15 investors · Other Health CareRule 506(b)
▶$946KraisedDec 2015 · 15 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Patrick PaceExecutive Officer, Director
- Bradley NybergDirector
- David JordenExecutive Officer, Director
- Glenn GoodrichExecutive Officer
- David BristolDirector
- Blair ShamelDirector
- Offering amount
- $1.2M
- Amount sold
- $946K
- First sale
- Dec 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$800KraisedAug 2014 · 15 investors · Other Health CareRule 506(b)
▶$800KraisedAug 2014 · 15 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Patrick PaceExecutive Officer, Director
- David BristolDirector
- Jennifer WestDirector
- Bradley NybergDirector
- Glenn GoodrichExecutive Officer
- David JordenExecutive Officer, Director
- Offering amount
- $800K
- Amount sold
- $800K
- First sale
- Aug 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 18 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2010 | $200K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2010 | $200K |
| National Science Foundation | Phase I | 2010 | $149.3K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2010 | $113.7K |
| U.S. Air ForceAir Force | Phase I | 2009 | $98.8K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2008 | $352K |
| U.S. Air ForceAir Force | Phase II | 2006 | $749.6K |
| National Science Foundation | Phase II | 2006 | $500K |
| U.S. Air ForceAir Force | Phase IISTTR | 2005 | $750K |
| National Science Foundation | Phase IISTTR | 2005 | $392.3K |
| U.S. Air ForceAir Force | Phase ISTTR | 2005 | $100K |
| U.S. Air ForceAir Force | Phase I | 2005 | $99.2K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2004 | $428.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2004 | $428.1K |
| National Science Foundation | Phase I | 2004 | $100K |
| U.S. Air ForceAir Force | Phase ISTTR | 2003 | $100K |
| National Science Foundation | Phase ISTTR | 2003 | $100K |
| National Science Foundation | Phase ISTTR | 2003 | $100K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Nanospectra do?
- Nanospectra Biosciences is a medical device company developing nanoparticle-based thermal ablation therapy that uses light-activated nanoshells to destroy solid tumors, such as prostate cancer, while sparing healthy tissue. Its technology targets clinical applications in tumor ablation, tissue treatment, and drug delivery.
- Who founded Nanospectra?
- Nanospectra was founded by Jennifer West.
- Who are Nanospectra's investors?
- Nanospectra's investors include Houston Angel Network.
- How much funding has Nanospectra raised?
- Nanospectra has disclosed $18.5M raised across 5 rounds.
- Where is Nanospectra headquartered?
- Nanospectra is headquartered in Houston, US.